A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update-Reference-Cited by-同舟云学术

A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update

Published:2013-04 Issue:6 Volume:49 Page:1287-1296
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Sternberg Cora N.,Hawkins Robert E.,Wagstaff John,Salman Pamela,Mardiak Jozef,Barrios Carlos H.,Zarba Juan J.,Gladkov Oleg A.,Lee Eunsik,Szczylik Cezary,McCann Lauren,Rubin Stephen D.,Chen Mei,Davis Ian D.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference32 articles.

1. Genetic and epigenetic alterations during renal carcinogenesis;Arai;Int J Clin Exp Pathol,2010

2. Renal cell carcinoma: current status and emerging therapies;Nelson;Cancer Treat Rev,2007

3. The Mainz classification of renal cell tumors;Diaz;Cancer Control,1999

4. Cancer statistics, 2010;Jemal;CA Cancer J Clin,2010

5. Estimates of cancer incidence and mortality in Europe in 2008;Ferlay;Eur J Cancer,2010

Cited by 394 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FDA-approved small molecule kinase inhibitors for cancer treatment (2001–2015): Medical indication, structural optimization, and binding mode Part I;Bioorganic & Medicinal Chemistry;2024-09

2. The treatment of metastatic renal cell carcinoma;Deutsches Ärzteblatt international;2024-08-23

3. Development of prognostic signatures and risk index related to lipid metabolism in ccRCC;Frontiers in Oncology;2024-06-13

4. Demographic Characteristics and Treatment Outcomes of Advanced Renal Cell Carcinoma With Clear Cell Histology: A Single-Center Experience From India;Cureus;2024-06-08

5. Combination immune checkpoint and targeted protein kinase inhibitors for the treatment of renal cell carcinomas;Pharmacological Research;2024-05